Ubiquinone-10 is a cellular endogenous antioxidant that resides in the epidermal layer. Ubiquinone-10 can increase the production of basal membrane components, fibroblast proliferation and protect cells from oxidative damage, so with increasing age, the amount of Ubiquinone-10 body will decrease. Bioavailability and permeability of Ubiquinone-10 are very low, thus affecting the potential efficacy and absorption in Ubiquinone-10. The preparation of Ubiquinone-10 formulation needs to be done to obtain products that have good bioavailability. Nanostructured Lipid Carrier (NLCs) is a modification of the SLN system, consisting of a certain amount of lipid matrix and liquid lipids. Mixtures of solid lipids and liquid lipids can provide space for drug trapping. The system will remain in solid form by controlling the concentration of the liquid lipids to be added into the formula so that the drug release process can be controlled.

Objective: An easy, perfect, specific and exact process has been studied for the simultaneous estimation of Glimepiride pure drug form as well as tablet dosage forms. Methods: A UV method for quantitative evaluation of Glimepiride by first order derivative peak detect method for determination in bulk as well as tablet dosage form is reported as there was a need to expand novel methods to analyze the drug. Results: Glimepiride has absorbance first derivative maxima at 225 nm in Methanol. Glimepiride follows Beer’s law in concentration range of 5-25µg/ml. The outcomes of the study were validated statistically and recovery studies were performed as per ICH guide lines. Conclusion: Thus the projected method can be applied competently for the estimation of Glimepiride in regular analysis in its dosage forms.

The ultimate goal of any oral drug delivery system is the successful delivery of the drug, in which almost 90% of the drugs are administered to the body for the treatment of various disorders and diseases as it is regarded as the safest, most convenient and most economical method of drug delivery having the highest patient compliance. The aim of the present study is to formulate sustained release matrix tablets of a model drug  (Tramadol hydrochloride) using HPMC 100 MCR, HPC and EC 7cps as rate retarding polymers, microcrystalline cellulose as bulking agent, magnesium stearate as lubricant and aerosil as glidant. Drug and polymer interactions were evaluated by using FTIR and DSC. The FTIR spectrum and DSC thermograms stated that drug and polymer are compatible to each other. Tablets were prepared by direct compression technique. The micromeritic properties of formulation mixtures of all the formulations were carried out and they were found to be as angle of repose (31.15⁰– 40.10⁰), bulk density (0.310g/ml-0.337g/ml), tapped density (0.355g/ml-0.59g/ml), Carr’s index (8.11%-15.3%), Hausner’s ratio (1.08-1.18) which are within the limits. The formulated tablets were physically acceptable and exhibited acceptable weight variation, friability.  In vitro dissolution studies were carried out using USP type-II dissolution apparatus and of all the formulations F₆ (containing HPMC and HPC in equal proportions) exhibited prolonged drug release for about 8 hrsas per the objective of the work. The percent drug content varied between 88% to 99%. It can be concluded from the study that the sustained release tablets can be better alternative over immediate release tablets by improving patient compliance and reducing frequency.

Solid lipid nanoparticles (SLN) containing Disease Modifying Antirheumatic drugs (DMARDs) Methotrexate (MTX) and Doxycycline (DOX) was developed using a triglyceride (tristearin) and a polaxamer (pluronic F68). Hot homogenization of melted lipid and aqueous phase at temperature above the melting point of lipid had produced SLN dispersion. Optimization of process and formulation variables have yielded SLN having an entrapment efficiency of 65.07%±1.23% and 79.56%±0.92% for MTX and DOX respectively. Particle size and zeta potential measured using Malvern Zetasizer showed 157.2nm and -9.6mv respectively for the optimized SLN formulation. The compatibility between the drug and the formulation excipients was tested by Fourier Transform Infrared Spectroscopy (FTIR) and found to be compatible. Powder X-ray diffraction (PXRD) study revealed that the drugs and lipid were dispersed in crystalline state in SLN. The in vitro drug release studies performed in phosphate buffer of pH 7.4 using dialysis bag showed a sustained release of both the drugs (>75%±1.4%) up to a period of two days. From the in vitro results, it can be concluded that SLN was found to be a suitable nano carrier for the incorporation of DMARDS: MTX and DOX without any significant interaction. The developed system produced sustained release of both the drugs (based on their concentration) for longer duration and thus suitable for the chronic inflammatory conditions of RA.

The purpose of this research is to determine the optimum composition of solid lipid and liquid lipid in order to increase the penetration and effectiveness of Q10 as antioxidant in anti-aging cosmetics. Solid lipid and liquid lipid used in this study were cetyl palmitate and caprylic, which were combined to four (4) different ratios, namely 10:0; 9:1; 7:3 and 5:5. NLC Q10 in this study was produced by high shear homogenization method at 3400 rpm for 5 cycles and at 24000 for 1 cycle. The fourth formula was evaluated in term of characteristics, penetration and effectiveness. From the pH test , it was known that all formulas met the skin pH range (4.0-6.0). For the particle size test , all formulas (NLC 1 – NLC 4) were in the range from 269.13 to 354.77 nm with NLC 3 (7: 3) had the smallest particle size. The results of viscosity and surface tension test  were also consistent with the theory, where the addition of liquid lipid reduced viscosity and surface tension of the system. The entrapment efficiency (EE) demonstrated the EE of NLC 1: 22.24%; NLC 2: 24.71%; NLC 3: 58.21% and NLC 4: 36.94%. The penetration test  showed all systems were able to penetrate the dermis layer at the 5^th hour. NLC 3 (7:3) had more rapid onset, while the NLC Q10 with the ratio of lipid 9:1, had slower onset of action but can penetrate farther than the other NLC Q10 system. The result of Q10 effectiveness test  showed NLC 2 (9:1) has lowest total macrophage (23.33) and very dense collagen observation (score : 4). From this research, it can be concluded that NLC 2 (9:1) had  the most optimal lipid composition to increase the penetration and effectiveness of Q10 as an antioxidant in anti-aging cosmetics.